Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Naglla Elimam"'
Autor:
Dania A. Monagel, Shatha S. Algahtani, Lian A. Karawagh, Wafa D. Althubaity, Sara A. Azab, Deena F. Haneef, Naglla Elimam
Publikováno v:
Frontiers in Pediatrics, Vol 11 (2023)
BackgroundSickle cell nephropathy (SCN) is a significant complication of sickle cell disease (SCD) with an asymptomatic onset in childhood and potential progression to chronic kidney disease (CKD). The clinical findings of SCN include hyposthenuria,
Externí odkaz:
https://doaj.org/article/6595ee9acb09446e8bed7e0d79f9103e
Autor:
Wasil Jastaniah, Naglla Elimam, Khalid Abdalla, Aeshah A. AlAzmi, Aml M. Elgaml, Ahmad Alkassar, Mustafa Daghistani, Sami Felimban
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-15 (2018)
Abstract Background Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we evaluated effects of
Externí odkaz:
https://doaj.org/article/5360adfac9934965b4bd6265988d5745
Autor:
Wasil Jastaniah, Naglla Elimam, Khalid Abdalla, Aeshah A. AlAzmi, Mohammed Aseeri, Sami Felimban
Publikováno v:
Leukemia Research Reports, Vol 10, Iss , Pp 44-51 (2018)
Sixty-three children (1–14 years of age) newly diagnosed with T-cell acute lymphoblastic leukemia were treated from January 2001 to December 2014. Patient outcomes were evaluated based on the regimen received; Capizzi methotrexate (C-MTX) vs. high-
Externí odkaz:
https://doaj.org/article/f78858e7dea84b4fbd0d9d22bdf0c16d
Publikováno v:
Journal of Pharmaceutical Research International. :1-13
Background: No existing research has addressed respiratory tract infections (RTIs) in children with non-neutropenic fever (NNF) who are present during seasons of religious mass gatherings (Hajj, Ramadan), especially if this coincides with the influen
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mohammed F Essa, Reem Abdellatif, Naglla Elimam, Waleed Ballourah, Reem Alsudairy, Mohammad Alkaiyat, Abdulrahman Alsultan, Wasil Jastaniah
Publikováno v:
Pediatric hematology and oncology. 39(7)
The management of Refractory/Relapsed B-cell Acute Lymphoblastic Leukemia (R/R ALL) remains challenging. Incorporating blinatumomab in R/R ALL treatment has shown encouraging results. We describe the outcome and predictors of response in children rec
PROGNOSIS OF PEDIATRIC NON HODGKIN LYMPHOMAS TREATED WITH FAB/LMB96 IN TERTIARY CENTER, SAUDI ARABIA
Autor:
Moussa Mohamed Shehadah, Naglla Elimam, Abdullah Baothman, Omima Abdullah Mustafa, Khalid Abdalla
Publikováno v:
American Journal of Health, Medicine and Nursing Practice. 5:67-82
Purpose: This study aimed at describing prognosis of pediatric B-NHL patients treated with FAB LMB-96 based protocol without dose modification, and to identify possible prognostic factors influencing the outcome and the treatment related toxicities.M
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:560-569
Background There are a limited number of studies that address non-neutropenic fever episodes in children with cancer, and no standard approach exists. Method We opt to retrospectively analyze the efficacy of the current clinical approach for manageme
Autor:
Saeed M. Bassem, Daniah E. Abdullatif, Abdullah Baothman, Waheed A. AlZhrani, Khursheed D. Ahmed, Abeer Almehdar, Naglla Elimam
Publikováno v:
Saudi medical journal. 42(12)
Objectives: To retrospectively review a small series of infant neuroblastoma (NBL) in a single Saudi medical institution over 10 years, including their presentation, management, and outcomes. Methods: Fifty-three subjects aged 0 to 14 years with prev
Autor:
Mohammed Burhan Abrar, Naglla Elimam, Aeshah AlAzmi, Omima Abdullah Mustafa, Khalid Abdalla, Wasil Jastaniah
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1831-1838
Background Outcomes of relapsed/refractory childhood acute leukemia remain poor. We analyzed the safety/efficacy of fludarabine, cytarabine, and granulocyte colony stimulating factor, with/without idarubicin (FLAG ± IDA) as salvage therapy compared